P2X7 Receptor Expression Levels Determine Lethal Effects of a Purine Based Danger Signal in T Lymphocytes
Overview
Cell Biology
Authors
Affiliations
Contact of T lymphocytes with nicotinamide adenine dinucleotide (NAD) or ATP causes cell death that requires expression of purinergic receptor P2X(7) (P2X(7)R). T cell subsets differ in their responses to NAD and ATP, which awaits a mechanistic explanation. Here, we show that sensitivity to ATP correlates with P2X(7)R expression levels in CD4 cells, CD8 cells and CD4(+)CD25(+) cells from both C57BL/6 and BALB/c mice. But P2X(7)R ligands do not only induce cell death but also shedding of CD62L. It is shown here that in CD62L(high) T cells, CD62L shedding correlates with low expression of P2X(7)Rs and lower cell death, whereas in CD62L(low) cells P2X(7)R expression and death are higher. The possibility is therefore investigated that P2X(7)Rs induce T cell activation. Experiments show that spontaneous T cell proliferation is somewhat higher in cells expressing P2X(7)Rs, but this effect we suggest is caused by P2X(7)R expression on accessory cells.
CD39 Is Expressed on Functional Effector and Tissue-resident Memory CD8+ T Cells.
Isaacs J, Degefu H, Chen T, Kleist S, Musial S, Ford M J Immunol. 2024; 213(5):588-599.
PMID: 38975728 PMC: 11333163. DOI: 10.4049/jimmunol.2400151.
P2X7 receptor activation impairs antitumour activity of natural killer cells.
Baroja-Mazo A, Penin-Franch A, Lucas-Ruiz F, Torre-Minguela C, Alarcon-Vila C, Hernandez-Caselles T Br J Pharmacol. 2022; 180(1):111-128.
PMID: 36098250 PMC: 10092446. DOI: 10.1111/bph.15951.
P2 Receptors: Novel Disease Markers and Metabolic Checkpoints in Immune Cells.
Vultaggio-Poma V, Di Virgilio F Biomolecules. 2022; 12(7).
PMID: 35883539 PMC: 9313346. DOI: 10.3390/biom12070983.
CD38 Correlates with an Immunosuppressive Treg Phenotype in Lupus-Prone Mice.
Perez-Lara J, Espinosa E, Santos-Argumedo L, Romero-Ramirez H, Lopez-Herrera G, Garcia-Garcia F Int J Mol Sci. 2021; 22(21).
PMID: 34769406 PMC: 8584421. DOI: 10.3390/ijms222111977.
A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling.
Hasan D, Shono A, van Kalken C, van der Spek P, Krenning E, Kotani T Purinergic Signal. 2021; 18(1):13-59.
PMID: 34757513 PMC: 8578920. DOI: 10.1007/s11302-021-09814-6.